エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2025.
Commission File Number: 001-40673
Cybin Inc.
(Exact Name of Registrant as Specified in Charter)
100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
INCORPORATION BY REFERENCE
Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-284173) of the Company, as amended or supplemented.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CYBIN INC. | ||
| (Registrant) | ||
| Date: September 17, 2025 | By: | /s/ Greg Cavers |
| Name: | Greg Cavers | |
| Title: | Chief Financial Officer | |
EXHIBIT INDEX
| 99.1 | Material Change Report dated September 3, 2025 |
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1. Name and Address of Company
Cybin Inc. (the "Company")
100 King Street West, Suite 5600
Toronto, Ontario
M5X 1C9
Item 2. Date of Material Change
September 2, 2025
Item 3. News Release
A news release with respect to the material change was disseminated by the Company on September 2, 2025 through Business Wire.
Item 4. Summary of Material Change
Effective September 2, 2025, Doug Drysdale stepped down as the Company's Chief Executive Officer. The Company's Co-Founder and President, Eric So, was appointed as Interim Chief Executive Officer by the Board of Directors.
Item 5. Full Description of Material Change
Effective September 2, 2025, Doug Drysdale stepped down as the Company's Chief Executive Officer. The Company's Co-Founder and President, Eric So, was appointed as Interim Chief Executive Officer by the Board of Directors.
Mr. So is a Co-Founder and Executive Chairman of the Company. He is a veteran owner, operator and investor in numerous companies over the last 20 years and has led corporate strategy, development, and finance at all stages of the business life cycle from start-up to growth stage and multinational.
The Board of Directors has established a committee to conduct a search for a new Chief Executive Officer. The Committee and the Board aim to move swiftly to bring onboard a new leader who will lead the Company through commercialization and ensure that the Company delivers on its commitment to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for patients.
Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7. Omitted Information
Not applicable.
Item 8. Executive Officer
Further information regarding the matters described in this report may be obtained from Gabriel Fahel, Chief Legal Officer of the Company, who is knowledgeable about the details of the material change and may be contacted at 1-866-292-4601.
Item 9. Date of Report
September 3, 2025.